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Abstract Hereditary syndromes causing colorectal cancer
include both polyposis and non-polyposis syndromes.
Overlapping phenotypes between the syndromes have been
recognized and this make targeted molecular testing for
single genes less favorable, instead there is a gaining
interest for multi-gene panel-based approaches detecting
both SNVs, indels and CNVs in the same assay. We
applied a panel including 19 CRC susceptibility genes to
91 individuals of six phenotypic subgroups. Targeted NGS-
based sequencing of the whole gene regions including
introns of the 19 genes was used. The individuals had a
family history of CRC or had a phenotype consistent with a
known CRC syndrome. The purpose of the study was to
demonstrate the diagnostic difficulties linked to genotype-
phenotype diversity and the benefits of using a gene panel.
Pathogenicity classification was carried out on 46 detected
variants. In total we detected sixteen pathogenic or likely
pathogenic variants and 30 variants of unknown clinical
significance. Four of the pathogenic or likely pathogenic
variants were found in BMPR1A in patients with unex-
plained familial adenomatous polyposis or atypical adeno-
matous polyposis, which extends the genotype-phenotype
spectrum for this gene. Nine patients had more than one
variant remaining after the filtration, including three with
truncating mutations in BMPR1A, PMS2 and AXIN2. CNVs
were found in three patients, in upstream regions of SMAD4,
MSH3 and CTNNB1, and one additional individual harbored
a 24.2 kb duplication in CDH1 intron1.
Keywords Colorectal cancer  FAP  Familial
adenomatous polyposis  Gene panel  Hereditary 
Colorectal cancer  Lynch syndrome
Introduction
Around 6 % of colorectal cancers (CRC) comprise hered-
itary syndromes for which high-penetrant mutations are
found in syndrome-specific genes [37]. Lynch syndrome,
familial adenomatous polyposis (FAP), MUTYH associ-
ated polyposis (MAP), Juvenile Polyposis syndrome (JPS),
PTEN hamartoma tumor syndrome and Peutz–Jeghers
syndrome (PJS) are among the most well known.
The introduction of next generation sequencing (NGS)
using whole-genome sequencing (WGS), whole-exome
sequencing (WES) and multigene panels have made it
possible to identify a spectrum of new mutations and also
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new causative genes in hereditary CRC. New syndromes
have been described like the recently reported, Polymerase
Proofreading-Associated Polyposis (PPAP) and NTHL1-
associated polyposis [31, 50]. Established syndromes with
unsolved causative genetic mechanisms are also gradually
being explored, which is the case for the hereditary mixed
polyposis syndrome (HMPS) [12, 51].
CRC syndromes have historically been defined based on
family history and/or genetics as well as tumor character-
istics. For hereditary non-polyposis colorectal cancer,
Amsterdam criteria, tumor testing for microsatellite insta-
bility (MSI) as well as presence of causative mutations in the
mis-match repair (MMR) genes, have been used for sub-
classification [19]. Overlaps in mutation spectrum between
polyposis and non-polyposis syndromes are also recognized.
The HMPS is characterized by the presence of polyps of
several histological types localized to the large bowel.
Adenomatous polyps as well as polyps of serrated or sessile
serrated type can be present. The JPS and HMPS may show
overlapping phenotypes and may appear indistinguishable
[13, 26]. In HMPS, duplications in the regulatory domain of
GREM1 were recently identified [12, 34], but except from
the GREM1 regulatory pathogenic duplications, also cau-
sativemutations inBMPR1A have been found [4].Mutations
in BMPR1A have also been reported in hereditary non-
polyposis CRC with microsatellite stable (MSS) tumors
(FCC type-X) [8, 29]. The duplication upstreamGREM1 in a
family with a few polyps of a more juvenile histology
reported by our group, demonstrates the complexity of the
phenotype-based classification of this syndrome [34].
Multigene panel testing in Lynch syndrome has recently
been used to identify mutations in unexpected high pene-
trant cancer-predisposing genes (e.g. BRCA1 and BRCA2)
[45, 54]. Several studies have also demonstrated cost
benefits as well as gain in mutation detection when using
multigene panels compared to analyses of single- or a few
genes [9, 39, 40, 45].
Additional research is required to understand the genetic
heterogeneity in these groups and the diversity in genotype
to phenotype correlations. In our study we used a multigene
CRC-panel consisting of 19 high risk- and moderate risk
genes as well as clinically less well defined genes in the
MMR system and the wnt signaling pathway [28, 48]. The
panel was applied to patients diagnosed with CRC divided
into six clinical subgroups. The classification into sub-
groups was based on family history and/or phenotype of
the disease. All patients had initially been referred for a
specific diagnostic test, Lynch syndrome or a polyposis
syndrome. The purpose of this study was to demonstrate
the diagnostic difficulties associated with genotype to
phenotype diversity. In the performed study, which also
included screening for large deletions and duplications, we
were able to demonstrate improved mutation detection
frequencies compared to conventional multi-step analyses.
The strategy also allowed for reduction in costs compared
to previously used screening procedures.
Materials and methods
Ninety-one index patients were included in this study.
Clinical characteristics of the index patients and families
are summarized in Supplementary Table 1. The medical
journals were reviewed and the patients were divided into
six clinical subgroups. All the patients were originally
referred for clinical FAP- and/or Lynch syndrome mutation
analyses during 2000–2015, but no mutations were iden-
tified in the genes analyzed. The subgroups were: (1) CRC
familial or unknown inheritance, not polyposis, (2) unex-
plained adenomatous polyposis[100 polyps, inheritance,
(3) unexplained adenomatous polyposis 1–100 polyps,
inheritance, (4) Unexplained adenomatous polyposis,
unknown inheritance, (5) familial or simplex atypical
polyposis/mixed polyposis/serrated polyposis and (6)
polymerase proofreading associated polyposis (PPAP). The
study has been approved by the local ethics committee at
the University of Gothenburg, Sweden.
DNA extraction, amplification and sanger-
sequencing
Genomic DNA was extracted using the BioRobot EZ1 (Qia-
gen, Hilden, Germany) with the EZ1 DNA Blood 350 ll kit
(Qiagen). Amplification, purification and Sanger sequencing
were carried out as described previously [14]. Primers used for
direct sequencing were identical to those used in the ampli-
fication reactions. All primer information is available upon
request. All variants found by capture NGS (Next Generation
Sequencing) were confirmed with Sanger sequencing.
Library preparation, hybridization capture
and MPS sequencing
DNA samples were quantified using the Qubit system (Life
Technologies, Carlsbad, CA, USA). Two lg of DNA were
fragmented using the Covaris S2 Ultrasonicator (Covaris,
Woburn, MA, USA), the samples were then analyzed on
the Bioanalyzer (Agilent Technology, Santa Clara, CA,
USA) for correct fragment sizes. The SureselectXT Cus-
tom 3-5.9 Mb library kit (Agilent Technology, Santa Clara,
CA, USA) was used for the capture and included 19 genes
APC, MUTYH, BMPR1A, SMAD4, STK11, PTEN, MLH1,
MSH2, MSH6, PMS2, EPCAM, CDH1 were all high risk
genes. MLH3, MSH3, PMS1,AXIN2, CTNNB1,CHEK2 and
MET were genes that are part of the MMR system, wnt
signaling and/or were found at the time of the development
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of the test to have an increased but not well defined risk
[24, 28, 44, 53]. Regions of 50 kb upstream and down-
stream of all genes and all intronic regions were included in
the target region. For the APC gene an additional region of
100 kb upstream was included, since causative deletions in
the promoter region have been found [23, 32, 35, 41]. For
the MET gene only coding exons were targeted. Eight
samples were pooled before capture and the concentration
of each pooled library was determined by using the Qubit
and the Bioanalyzer. Sequencing was performed on the
Illumina HiSeq 2000 (Illumina, San Diego, CA, USA) with
2 9 94 or 2 9 97 bp paired end reads.
Analysis of sequencing data
An in-house analysis pipeline was used in which the main
steps after demultiplexing included read alignment to the
reference human genome hs37d5ss (1000 genome with
decoy sequences) by Novoalign, marking of PCR dupli-
cates (Picard tools, http://picard.sourceforge.net) and
quality score recalibration, indel realignment and variant
calling performed with the Genome Analysis Tool Kit
(GATK) package [27]. For all samples and positive con-
trols variants were called with GATK UnifiedGenotyper
with a call confidence of 10.
Copy number variation (CNV) analysis
The CNV analysis was based on read depth, one read-pair
represents one data point in a sliding window over the
target region. A normalized coverage depth ratio including
GC-normalization between a sample and an average of 23
normal samples (baseline) were computed. Detection of
abnormal coverage ratios were found by visual inspection
of plots of the coverage ratios over the targeted regions.
Deletions were detected as a lower coverage (cut off 0.75)
and duplication as a higher coverage (cut off 1.25).
Regions with an abnormal coverage ratio were further
inspected in IGV (Integrative Genomics Viewer) and
breakpoints were analyzed [33].
Filtration of variants and databases
Variants in exons and in ± 20 bp flanking intronic
sequences were evaluated for pathogenicity. Truncating
nonsense, frameshift indels and variants located in consen-
sus splice-acceptor and-donor sites were presumed and
evaluated as disease causing. All other variants, synony-
mous and non-synonymous, were compared with the fol-
lowing public databases; the Single Nucleotide
Polymorphism database (dbSNP) together with 1000 Gen-
omes [1], the National Heart, Lung and Blood Institute
(NHLBI) Exome Sequencing Project (ESP) (http://evs.gs.
washington.edu/EVS/), ExAc (Exome Aggregation Con-
sortium, Cambridge, MA (URL: http://exac.broadinstitute.
org) [20 (02, 2014) accessed]), TCGA data (www.cbio
portal.org) and with in-house information. Variants with a
minor allele frequency (MAF) of B1 % were further ana-
lyzed, the rest of the variants were treated as polymor-
phisms, this also included likely benign variants. Thirty-two
missense variants with an MAF B1 % were classified based
on three in silico protein prediction tools, SIFT, PolyPhen-2
and CADD. SIFT (Sorting Intolerant From Tolerant) pre-
dicts a damaging mutation if the score is B0.05, and toler-
ated if the score is[0.05 [20]. PolyPhen-2 (Polymorphism
Phenotyping version 2), predicts probably damaging and
possibly damaging mutations with a higher confidence if
values are near 1 [3]. The Combined Annotation Dependent
Depletion (CADD) is a method to measure deleteriousness
by comparing the annotation of fixed or almost fixed derived
alleles with those of simulated variants. Several parameters
are taken into account when using CADD, including, allelic
diversity, annotation and functionality, pathogenicity, dis-
ease severity, experimentally measured regulatory effects,
complex trait associations and highly ranked known patho-
genic variants within individual genomes. Variants that are
more likely to be observed in the genome are proposed to be
more benign while variants that are more likely to be sim-
ulated (not observed) are proposed to have a more delete-
rious effect. This is measured in a Phred-like scale C-score,
were a score of 10 represents the 10 % most deleterious
substitutions that can be done to the human genome and a
score of 20 represents the 1 % most deleterious variants.
Higher score is associated with a higher probability of a
deleterious effect with a recommended cut-off at 15 [16].
Classification of variants by the InSiGHT database [46]
was considered correct. For variants not included in this
database published literature and classification done by
HGMD [42] as well as Leiden open source variation
(LOVD) databases and also ClinVar [22] were used in
combination with in-house information to make a manual
classification. The manual classification criteria was used
according to the five-class system following guidelines
from the International Agency for Research on Cancer
(IARC): 1 = Benign, 2 = Likely benign, 3 = Variant of
Unknown clinical Significance (VUS), 4 = Likely patho-
genic and 5 = Pathogenic.
Results
The gene panel was applied to 91 patients, previously tested
negative for mutations in the polyposis genes (APC,
MUTYH, BMPR1A, SMAD4, STK11) and/or a combination
of different MMR genes (MLH1, MSH2, MSH6, PMS2,)
depending on the primary indication when the referral was
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issued. The patients were sub-grouped based on their clin-
ical characteristics (Supplementary Table 1). Sequencing
was performed over the entire gene regions as described and
all coding regions were covered at least 30 9 except for
CDH1 ex1, EPCAM ex1,MSH3, ex1 andMLH1 ex12 which
in five samples were covered at least 25x. For the whole
targeted region the mean coverage was 417x in all 91
samples. The analyses of variants included the coding
region and ± 20 bp of intronic sequences. The CNV anal-
ysis was based on the entire covered gene regions.
In total 8 pathogenic class 5 and 8 likely pathogenic class
4 variants were found (Tables 1, 2). This gives a mutation
detection frequency of 8.8 % (8/91) for the class 5 variants
only and a frequency of 17.6 % (16/91) when also class 4
variants are included. These results are in concordance with
the results obtained in other studies of similar gene panels
[6, 18]. Two pathogenic variants in PMS2 in patients I:26
and I:50 were missed in the initial analyses of the MMR
genes performed in an external laboratory. Thirty-two
missense variants, all of them found in a heterozygote state,
with MAF B1 %, according to the filtration criteria, were
analyzed and classified manually or according to the
InSiGHT database [46] in the case the variant was included
in this database. The results are presented in Table 2 and
include four class 5 pathogenic variants, two likely patho-
genic class 4 variants and 26 class 3 variants of unknown
clinical significance (VUS). The APC variant, c.1902
T[G, was recently found to have amajor splicing effect on
exon 14 resulting in loss of this exon [10]. The variant was
found in a patient (III:61) with unexplained familial ade-
nomatous polyposis (1–100 polyps), this patient also had a
VUS, APC c.4472T[A, p.Phe1491Tyr. Both of these
variants segregated with affected individuals and neither of
them were found among healthy individuals from the fam-
ily. Two class 5 variants were found inMUTYH, one each in
patients III:71 and I:42, respectively. The c.536A[G,
p.Tyr179Cys and c.1187G[A, p.Gly396Asp were found
in a heterozygote state and are classified as pathogenic if
found homozygote or in a compound heterozygote state.
Nine patients hadmore than one variant remaining after the
filtration, including threewith truncating variants inBMPR1A,
PMS2 and AXIN2. The BMPR1A c.969delT variant (Table 1)
was found togetherwith one likely pathogenic variant (class 4)
in CHEK2 c.470T[C, p.Ille157Thr (Table 2), in an mixed
polyposis case (V:87), additionally this patient carried a
CHEK2 VUS, c.190G[A, p.Glu64Lys (Table 2). A trun-
cating variant in PMS2 c.861_864del (Table 1) was found
together with the VUS APC c.7402T[C, p.Ser2468Pro
(Table 2) in patient I:50. The AXIN2 c.254del (Table 1)
variant and the synonymous VUS MSH2 c.1275A[G
(Table 2) were both found in patient I:55.
Tumor characteristics e.g. MSI and IHC can be of value
for interpretation of theVUS. For 52 of these patients we had T
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results from only MSI tests or for both MSI and IHC tests
(Supplementary Table 1).When investigating the VUS pre-
sent among these patients there are some findings. Patient
I:47 has a tumorwhich isMSI-H and present a loss ofMLH1/
PMS2 proteins, this patient has a VUS in MLH3,
c.1870G[C, p.Glu624Gln. This VUS was also found in
two patients with an MSS (I:8, I:10) tumour phenotype. The
variant is interpreted differently between the in silico protein
predication tools used, it has a low CADD score (17) and is
quite common in the ExAc population database (0.73 %).
Since tumors from patients with this variant can be bothMSI
orMSS, it is difficult to conclude the pathogenic effect of the
variant. In two patients with aMSI-H tumour phenotype, one
MSH6:c.3226C[T, p.Arg1076Cys (I:56) and one
MSH2:c.2013T[A, p.Asn671Lys (I:92) VUS were found.
These variants are predicted damaging by all in silico protein
predication tools, exhibit a high CADD score (32 respec-
tively 28.2) and are rare (0.0091 %) or not present in the
population database ExAc. Both variants might be predicted
to have a likely pathogenic effect. TCGA data (www.cbio
portal.org) shows a high functional impact for the MSH6
variant. In the patients with an MSS tumor phenotype, eight
unique MMR variants were found. The variants exhibit
conflicting in silico protein predication results. Combined
with a lower CADD score in general, the variants might be
predicted to have a likely benign effect, consistent with their
MSS phenotype.
Four structural variants were found and they are pre-
sented in Table 3. An individual (patient III:65) from a
family with phenotypic AFAP was found to carry a 1.9 kb
heterozygote deletion located 2 kb upstream of SMAD4
(hg19/chr18:g.48537165_48539080del). The deleted region
includes an insulator element 200 bp in size
(chr18:g.48537803-48538002). Additional upstream dele-
tions were found in MSH3 (I:34) and CTNNB1 (I:57).
Another patient (I:6) had a 24.2 kb duplication in CDH1
intron 1 (hg19/Chr16:g.68802080_68826280del).
Discussion
In this study we show the importance of using multigene
panels which allows for a parallel comprehensive screening
for CRC syndromes. Mutations in BMPR1A have been
found in an extended phenotypic spectrum beyond juvenile
polyposis, including HMPS, AFAP simplex, familial col-
orectal cancer type X (FCCX) and early onset CRC without
familial history and MSI negative tumours [4, 8, 29, 30].
To this spectrum we add a patient with an atypical poly-
posis (V:87, this patient also carries two CHEK2 variants,
Table 2) and three patient with unexplained adenomatous
polyposis and different number of polyps. Patient IV:76
had a splice-site variant c.230 ? 2T[C (class 4), II:59
had a truncating variant, c.441delT, Phe147Leufs*18 (class
5) and the last patient (II:58) had a probable pathogenic
(class 4) missense mutation, c.1409 C[T, p.Met470Thr in
BMPR1A. This missense mutation has previously been
found in a patient with a juvenile polyposis phenotype and
around 300 polyps throughout the entire gastrointestinal
tract [15]. Two patients from Group I, ‘‘CRC familial or
unknown inheritance not polyposis’’, had variants in
AXIN2. In one of these patient with late onset of CRC a
truncating AXIN2 variant was found together with an
MSH2 variant of unknown significance (I:55). The second
patient (I:11) presented with an AXIN2 missense variant
c.2051C[T, p.Ala684Val. Variants in AXIN2 have been
reported in patients with CRC and oligodentia and in
patients with oligodentia solely [21, 52]. It is suggested that
truncating pathogenic variants in AXIN2 are more likely to
predispose carriers to syndromic oligodontia and colorectal
cancer compared to missense variants [25]. To our
knowledge oligodonita was not present in any of our
patients.
We found a large deletion in the regulatory region of
SMAD4 in a patient with unexplained adenomatous poly-
posis (1–100 polyps) (III:65). An insulator element that
may act as a barrier to enhancer action is located in the
deleted region. Transcription of genes beyond the insulator
is not stimulated by the enhancer when the insulator is
active. This deletion might therefore have an effect on the
expression of the gene. In a recent study two SMAD4
mutations in patients without juvenile polyps were identi-
fied, one with around 20–99 adenomatous polyps and the
other one without reported polyps, which further extends
the phenotypical spectrum for this gene [6].
Table 3 Structural variations detected among 91 index patients
Clinical group:
patient number
Location Genomic position (GRCh37/hg19)/dbSNP (rs) Approximate
size (kb)
Classification*
III:65 Upstream SMAD4 hg19/chr18:g.48537165_48539080del 1.9 3
I:6 Intron 1 CDH1 hg19/Chr16:g.68802080_68826280dup 24.2 3
I:34 Upstream MSH3 hg19/Chr5:g.79902126_79904625del 2.5 3
I:57 Upstream CTNNB1 hg19/Chr3:g.41200986_41203204del 2.2 3
* manual classification
200 A. Rohlin et al.
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There is a complexity of combinations of possible ligand
receptors and downstream effectors in the BMP/TGFR-b
signalling pathways and this might explain part of the
genotype-phenotype relationship. There might also be a
genotype-phenotype correlation depending on where in the
gene the mutation is located. Several genes in the BMP/
TGFR-b signalling pathway are mutated in hereditary CRC
as well as sporadic CRC and possibly inactivation of also
other genes in this pathway might predispose carriers to
CRC. It seems as if patients with mutations in APC,
BMPR1A, SMAD4 and GREM1 can have similar polyposis
phenotypes but carriers of GREM1 mutation with HMPS
might not have the same risk for extra-colonic disease as
patients with BMPR1A mutations and HMPS [47].
In a recent multigene-panel based CRC study 1.4 % (8/
586) had CHEK2 risk alleles or truncating mutations, two of
the patients had the c.470T[C, p.Ile157Thr, variant and
four c.1100delC alleles, all had polyps or CRC, none of them
had a personal history of breast cancer, but six had at least
one family member with breast cancer [6]. Around 2 % (2/
91) of our patients had CHEK2 variants, V:87 had both
c.190G[A, p.Glu64Lys and c.470T[C, p.Ile157Thr and
I:20 had the splice variant c.319 ? 2T[A, and they did
present with polyps or CRC but no breast cancer has been
reported in the families as we know of. Variants in CHEK2
still remain of uncertain clinical relevance as is further
emphasized by the fact that V:87 also carried a truncating
probably pathogenic variant in the BMPR1A gene
(c.969delT). In a recent study CHEK2 variants have been
found among individuals with various types of cancer,
which might be partly due to the high population frequency
of the common CHEK2 variants (c.1100delC and
p.Ile157Thr) [45].
The truncating MLH3 mutation c.3563 C[G,
p.Ser1188* was found in homozygote state in an unex-
plained polyposis case (IV:69) with duodenal polyps and
CRC. The MLH3 protein as well as the PMS1 protein can
dimerize with MLH1 and assist in single nucleotide mis-
match DNA-repair, but their roles are not well understood
[38]. Variants in the genes have been found in patients
without a family history, in some cases also in sporadic
patients and/or in healthy controls. Variants have also been
found together with other MMR gene variants, suggesting
PMS1 and MLH3 to be low risk genes in Lynch syndrome
[17]. The clinical significance of the variant we report here,
is therefore difficult to estimate. However, recently com-
pound heterozygote loss of function (LoF) germline
mutations in the MSH3 gene were identified in patients
with an unexplained adenomatous polyposis. The data
presented by Adam et al. strongly support disease causing
MSH3 mutations to follow a recessive mode of inheritance
[2]. A comparable scenario might possibly also be con-
sidered for mutations in MLH3.
When comparing the VUS in the MMR genes to the
corresponding results from the MSI and IHC test of the
tumours, some conclusion might be drawn concerning the
pathogenicity. Two variants, one in MSH6 c.3226C[T,
p.Arg1076Cys (I:56) and one in MSH2 c.2013T[A,
p.Asn671Lys (I:92), that were identified in patients who
presented with a MSI-H phenotype (no IHC results were
available), might be predicted to be likely pathogenic. Both
of these variants are predicted damaging by all the protein
predication tools used, they also have a very high CADD
score and are very rare or not present in the population
database ExAc. TCGA data shows a high functional impact
for the MSH6 variant. It is feasible to predict these variants
as presumably likely pathogenic at this point until more
functional data is available.
The patient (I:6) with the intronic duplication in
CDH1also had breast cancer. It is known that CDH1
mutations can be found in patients with lobular breast
cancer and in hereditary diffuse gastric cancer. Although
no obvious functional elements are found in this region it
cannot be ruled out that the duplication has an effect on the
transcription or regulation of the gene.
The search for germ-line mutations in risk individuals
have been focused on mutations associated with highly
penetrant disease phenotypes, which include a stepwise
approach leading to an expensive strategy and underesti-
mation of familial cases [43]. The increased use of multi-
gene panels have already shown a higher mutation
detection rate compared with traditional testing based on
clinical criteria [6, 18], as is also confirmed by this study.
The reason for this is probably a large genetic hetero-
geneity and overlapping clinical presentation of the dif-
ferent CRC syndromes. Limited knowledge of the medical
and/or family history or an atypical presentation of the
CRC syndromes might lead to an incorrect diagnosis of
patients. The possibility of panel-based testing is beneficial
not only for the patient but also for time and cost savings.
However, there is also a complexity of information that can
result from a multigene-panel test. Variants may also be
coincidental or explain only part of the clinical phenotype.
Segregation analyses could in these cases be used to further
understand the clinical significance of variants. In this
study, when also structural variants are included, in total
33 % (30/91) of the patients have at least one VUS. When
eliminating those with a disease-causing variant already
identified 29 % (26/91) of the patients have a VUS of
which the majority are located in MMR genes, in concor-
dance also with other reports [6]. A patient without iden-
tified mutation in this study could have mutations in high
penetrant recently identified genes, which were not inclu-
ded in this panel. Several candidate genes for both poly-
posis and non-polyposis syndromes have been identified
[5, 11]. Multigene panels used for detection of pathogenic
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variants in CRC syndromes frequently include genes for
which the cancer risk is not well known and management
guidelines are not yet established. Classifying the genes
into different categories based on these issues might be
advisable [7]. The implementation of multigene-panel
based technology into the clinic implies new opportunities
and challenges which might also require introduction of
new models for genetic counselling.
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